Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription

Miao Wang1, Chen Guo1, Liang Wang1, Gang Luo1, Chao Huang1, Yawei Li1, Dong Liu1, Fuqing Zeng1, Guosong Jiang1 and Xingyuan Xiao1

Abstract
Aberrant expression of long noncoding RNA GAS5 in bladder cancer (BC) cells was identified in recent studies. However, the regulatory functions and underlying molecular mechanisms of GAS5 in BC development remain unclear. Here, we confirmed that there was a negative correlation between GAS5 level and bladder tumor clinical stage. Functionally, overexpression of GAS5 reduced cell viability and induced cell apoptosis in T24 and EJ bladder cancer cells. Mechanistically, GAS5 effectively repressed EZH2 transcription by directly interacting with E2F4 and recruiting E2F4 to EZH2 promoter. We previously reported that miR-101 induced the apoptosis of BC cells by inhibiting the expression of EZH2. Interestingly, the present study showed that downregulation of EZH2 by GAS5 resulted in overexpression of miR-101 in T24 and EJ cells. Furthermore, the level of GAS5 was increased under the treatment of Gambogic acid (GA), a promising natural anti-cancer compound, whereas knockdown of GAS5 suppressed the inhibitory effect of GA on cell viability and abolished GA-induced apoptosis in T24 and EJ cells. Taken together, our findings demonstrated a tumor-suppressor role of GAS5 by inhibiting EZH2 on transcriptional level, and additionally provided a novel therapeutic strategy for treating human bladder cancer.

Introduction
Bladder cancer (BC) is the most common malignancy of the urinary system with an estimated 429,000 new cases and 165,000 deaths annually in the world. Endoscopic resection is generally employed in non-muscle-invasion BC which is often followed by adjuvant chemotherapy. Meanwhile, radical cystectomy is used for treating muscle-invasive BC. However, current primary treatments cannot prevent BC recurrence or progression in high-risk patients. Overall survival of BC remains at a low level, indicating the need for a better knowledge of the molecular basis of BC and exploration of innovative therapeutic strategies.

A major class of newly identified transcripts, long noncoding RNAs (lncRNAs), have been found to drive many important cancer phenotypes. Accumulating studies demonstrated that lncRNAs regulated proliferation, metastasis and apoptosis of tumor cells. Out of numerous cancer-related lncRNAs, growth arrest-specific 5 (GAS5), whose gene is located at chromosome 1q25.1, plays an essential role in the regulation of cancer cell survival. Previous studies reported that GAS5 lowly expressed in various neoplasm (e.g., skin cancer, breast cancer and bladder cancer) and was associated with cell cycle arrest and apoptosis of tumor cells. Recently, Zhang et al found that overexpression of GAS5 promoted apoptosis in drug-resistant BC. These findings indicated a potential role for GAS5 in BC. However, the underlying molecular mechanisms remain unknown, and the
Fig. 1 (See legend on next page.)
expression of GAS5 after the treatment with anti-cancer agent in BC cells has not been investigated.

LncRNAs had been demonstrated to interact with the polycomb repressive complex 2 (PRC2) to reprogram chromatin state and regulate cancer invasiveness and metastasis\(^{11,12}\). The enhancer of zeste homolog 2 (EZH2), as a constitution of PRC2, is a histone 3 lysine 27 (H3K27) methyltransferase\(^{13}\). EZH2 is ectopically expressed in BC cells to facilitate BC development and progression\(^9,10\). Our previous work showed that inhibition of EZH2 could promote BC cell apoptosis after the treatment with Gambogic acid (GA), a natural plant ingredient\(^{14}\). It has been well acknowledged that LncRNAs regulated the development of BC though the regulatory interactions with EZH2. Upregulated lncRNA H19 promoted BC cell metastasis by increasing the binding of EZH2 and H3K27me3 with the Nkd1 promoter\(^{15}\). LncRNA HOTAIR regulated metastatic progression by associating with PRC2 subunits SUZ12 or/and EZH2\(^{11}\). However, whether LncRNAs participate the regulation of the transcription of EZH2 in BC has yet to be studied.

In this study, we showed that GAS5 expression level was negatively related to clinical stage of BC. GAS5 inhibited EZH2 transcription by interacting with transcription factor E2F4 to promote BC cells apoptosis. Moreover, GAS5 acted as a key factor in GA-induced apoptosis of BC cells.

### Results

**GAS5 was lowly expressed in human BC tissues**

LncRNA GAS5 (GAS5-001) and other two isoforms (GAS5-005 and GAS5-007) were studied here. We evaluated the expression levels of different transcripts of GAS5 in 43 pairs of bladder urothelial carcinoma samples and their adjacent normal bladder tissues from BC patients at different stages. A significant downregulation of GAS5 (GAS5-001) level was observed in 33 out of 43 (76.7%) BC tissues, with the overall mean level of GAS5 (GAS5-001) 3-fold lower than that of the adjacent normal bladder tissues. By contrast, the levels of GAS5-005 and GAS5-007 were significantly increased in BC tissues (Fig. 1a). Our findings are consistent with previous study that GAS5 (GAS5-001) acts as a tumor-suppressive GAS5 transcript, and GAS5-007 is an oncogenic GAS5 transcript in some other tumor types\(^{16}\). GAS5 (GAS5-001) was single out for further studies. As shown in Table 1, a distinct relationship was found between low GAS5 expression and invasive potential of BC \((P < 0.001)\). The data highlights the role of GAS5 as a crucial cancer-suppressor in BC.

### Upregulation of GAS5 suppressed viability and promoted apoptosis of BC cells in vitro

Given that GAS5 is downregulated in BC tissues in our study, we further explored the effects of GAS5 on BC cell biological activity. GV144 and GV144-GAS5 were
transfected into T24 and EJ cells, the mRNA expression levels of GAS5 were significantly increased in both T24 and EJ cells after transfection of GV144-GAS5 (Fig. 1b). MTT assays were performed and results showed that transfection of GV144-GAS5 significantly decreased cell viabilities of T24 and EJ cells in a time-dependent manner (Fig. 1c). On the other hand, flow cytometric assays were performed to study the effect of GAS5 on the apoptosis of BC cell lines. Forced expression of GAS5 promoted cell apoptosis rates in T24 and EJ cells (Fig. 1d). Consistently, 72 h after transfection of GV144-GAS5, Western-blot assays were performed and apoptotic executive protein caspase-3 was found to be activated in both BC cell lines (Fig. 1e).

**Knockdown of GAS5 inhibited GA-induced apoptosis of BC cells**

GA is increasingly recognized as novel and promising natural anti-cancer compound for BC14,17,18. Here, we investigated the potential role of GAS5 in anti-cancer compound GA-induced apoptosis of BC cells. Both T24 and EJ cells were treated with different concentrations of GA (0, 1.5, 2, 2.5 μM) for 24 h or 48 h respectively, we found GAS5 expressions were significantly increased by the treatment of GA in a both time-dependent and dose-dependent manner (Fig. 2a). Next, we explored whether GAS5 affected GA-induced apoptosis of BC cells. GAS5-siRNA-1 and GAS5-siRNA-2 were transfected into BC cells, and effectively suppressed GAS5 levels (Fig. 2b). MTT assays showed that knockdown of GAS5 reversed GA-induced inhibition on cell viability (Fig. 2c). Flow cytometric assays revealed that knockdown of GAS5 repressed GA-induced cell apoptosis (Fig. 2d). These observations demonstrated that GAS5 was a crucial factor in the anti-cancer effect of GA in BC cells, which also suggested that GAS5 is an attractive chemotherapeutic target in future BC treatment.

**Upregulation of GAS5 inhibited EZH2 transcription in BC cells**

Our previous work and several other studies have demonstrated that EZH2 is an essential factor in regulating cell biological activity in BC14,19,20. Additionally, both EZH2 and GAS5 have involved GA-induced BC cell apoptosis14. Therefore, we investigated whether GAS5 influences the expression of EZH2. GV144-GAS5 was stably transfected into T24 and EJ cells, and forced expression of GAS5 markedly downregulated EZH2 protein level (Fig. 3a). GAS5 shRNA were subsequently transfected into EJ and T24 cells. As shown in Fig. 3b, transfection of GAS5 shRNA reversed GA-induced downregulation of EZH2 protein and the activation of caspase-3, when compared with negative control. Accordingly, forced expression of GAS5 restrained EZH2 mRNA expression (Fig. 3c), and knockdown of GAS5 restored GA-induced suppression of EZH2 mRNA expression in T24 and EJ cells (Fig. 3d). To illustrate the mechanism of regulation of EZH2 expression by GAS5, human EZH2 luciferase reporter plasmid was used for luciferase reporter assay. Forced expression of GAS5 resulted in a decreased promoter activity of EZH2 in EJ and T24 cells (Fig. 3e). Meanwhile, knockdown of GAS5 reversed the downregulation of transcriptional activity of EZH2 mRNA which was induced by GA treatment (Fig. 3f). These results proved that GAS5 negatively regulated EZH2 transcription in BC.

**GAS5 downregulated transcriptional expression of EZH2 through recruitment of E2F4 in BC cells**

EZH2 transcription is regulated by several transcription factors such as E2F2,21,22. We found that there were two E2F-binding sites in EZH2 promoters (Fig. 4a). The E2F family is mainly comprised of 5 members (E2F1-5). Though both E2F1 and E2F4 could bind to EZH2 promoter, the CHIP assay showed that only E2F4’s binding capacity was improved evidently with GAS5 overexpression (Fig. 4b). In addition, E2F4 is the most abundant of all E2Fs, and E2F4-loss plays a key role in suppressing bladder carcinogenesis23. Therefore, E2F4 was chosen as the object of our study. E2F4 was then knockdown by siRNA, and the results of RT-qPCR and western blot revealed that EZH2 expression was significantly upregulated (Fig. 4c, d). Following that, RNA immunoprecipitation (RIP) assay was performed, which demonstrated that E2F4 protein could bind to GAS5 (Fig. 4e). The direct interaction between E2F4 and GAS5 was further verified by applying total protein (Fig. 4f) and GST-E2F4 fusion protein (Fig. 4g) to GAS5 pull-down assay. In addition, we found GAS5 did not impact the expression of E2F4 protein and E2F4 mRNA (Fig. 4h, i). Taken together, we concluded that GAS5 inhibited EZH2 transcriptional activity by recruiting transcription factor E2F4 to EZH2 promoter.

**Knockdown of EZH2 improved miR-101 transcriptional activity and overexpression of EZH2 suppressed GA-stimulated upregulation of miR-101**

It is generally recognized that miR-101 inhibits EZH2 by directly targeting to its 3’-UTR24. But a recent study discovered that EZH2 suppressed miR-101 transcription reversely in hepatocellular carcinoma25. We sought out to examine this theory in BC. We blocked EZH2 expression in T24 and EJ cells by stable transfection of EZH2 shRNA (Fig. 5a), subsequently RT-qPCR indicated that miR-101 expression was upregulated (Fig. 5b). To verify the effect of EZH2 on miR-101 transcription, human miR-101-2 reporter plasmid was transfected into T24 and EJ cells for luciferase reporter assay. It indicated that transcriptional
Fig. 2 (See legend on next page.)
activity of miR-101 was significantly increased by knockdown of EZH2 (Fig. 5c). The results suggested that downregulation of EZH2 enhanced miR-101 expression by improving miR-101 transcriptional activity.

Next, EZH2 was stably overexpressed in T24 and EJ cells by transfection of PC3.1-EZH2 (Fig. 5d). 2.0 μM GA or equal volume of PBS was then treated. Forty eight hours later, RT-qPCR revealed that GA upregulated miR-101 expression. However, that effect was significantly suppressed by overexpression of EZH2 (Fig. 5e). Consistently, similar results were observed by luciferase reporter assay (Fig. 5f). These results suggested that overexpression of EZH2 restored GA-induced upregulation of miR-101.

Knockdown of GAS5 suppressed GA-induced growth inhibition of BC in vivo

Finally, we assessed the effects of GAS5 on bladder xenograft tumors and its effect on GA-induced growth inhibition of bladder xenograft tumor. The tumors were removed, weighed (Fig. 6a) and photographed (Fig. 6b). It is obvious that tumor growth was inhibited by GA and promoted by knockdown of GAS5. The inhibitive effect of GA was reversed by knockdown of GAS5. Total RNA was extracted from the tumor tissues and RT-qPCR illustrated that GA decreased EZH2 mRNA expression and increased miR-101 expression, but these effects were significantly suppressed by knockdown of GAS5 (Fig. 6c). Moreover, immunohistochemistry and Western-blots indicated that GA-induced downregulation of EZH2 protein was abolished by knockdown of GAS5 (Fig. 6d, e).

Discussion

Increasing data proved that lncRNAs participated in BC’s formation, progression, and metastasis. The human H19 gene is the first lncRNA that is found to be oncogene in the bladder, which is rarely expressed in adult tissue, but highly expressed in BC. Since then, emerging lncRNAs such as MALAT1, TUG1, and UCA1 had been demonstrated to be tumor markers or prognostic indicators of BC. Meanwhile, it has been previously demonstrated that downregulated IncRNA MEG3 activates autophagy and increases cell proliferation in BC. Forced expression of MEG3 inhibits tumor cell proliferation and colony formation by inducing accumulation of p53 protein. Here, we confirmed that IncRNA-GAS5 was lowly expressed in BC tissues, and further demonstrated that lower GAS5 levels were associated with poor prognosis in BC. It has been reported that GAS5 inhibited cell proliferation by regulating the expression of CDK6 and CCL1 in BC. In the present study, our results showed that upregulation of GAS5 promoted apoptosis of BC cells. Furthermore, we found that GAS5 inhibited EZH2 transcription by recruiting transcription factor E2F4 to EZH2 promoter, and suppression of GAS5 reversed the growth inhibition effects of GA on BC both in vivo and in vitro. These findings shed new light on a novel tumor-suppressing mechanism for GAS5 in BC.

Although the function of the vast majority of lncRNAs remains to be identified, it is demonstrated that several lncRNAs can regulate the binding of transcription factors or transcriptional repressors to gene promoters and thereby cause gene activation or silencing. Previous study also found that GAS5 bound to transcription factor GR (glucocorticoid receptor) and titrated it away from its target gene promoters. RNA-seq data showed several lncRNAs regulated cell cycle gene expression by targeting E2F transcription factors in breast cancer. E2Fs are frequently amplified and overexpressed in numerous cancers, and the activation of E2Fs is an important molecular feature of human BC. E2F activity is regulated by pocket proteins (Rb, p107 and p130), HDAC and Brg, which bind to E2Fs in their active under-phosphorylated form, and inhibit the transcription of E2Fs target genes. Our latest research demonstrated GAS5 interacted with E2F1 and enhanced the binding of E2F1 to the promoter of P27Kip1, which is a known regulator of cell cycle. Here, we explored the role of E2Fs associated with GAS5 in BC. Our data showed GAS5 could directly interact with E2F4. ChIP assay showed that GAS5 enhanced the binding of E2F4 to EZH2 promoter. Thus, we concluded that by recruitment of E2F4 to EZH2 promoter, upregulated GAS5 inhibited transcription of EZH2. Our research further develops the understanding of the regulatory function of GAS5 on the transcription of downstream genes in BC.

EZH2 is a histone methyltransferase component of the PRC2. Both gain- and loss-of-function mutations of EZH2 have been involved in tumorigenesis. Though...
downregulation and loss-of-function mutations suggest tumor suppressive activity of EZH2 in some cancers, evidence to demonstrate that EZH2 with gain-of-function mutations act as oncogene in numerous others, such as prostate cancer, breast cancer and BC37. Previously, we demonstrated that BRD4 facilitated EZH2 transcription through the recruitment of C-MYC to EZH2 promoter19. The E2Fs also have been reported to manipulate EZH2
Fig. 4 (See legend on next page.)
transcription in several malignancies including BC. Rb/RB1 phosphorylation activated the expression of EZH2 through direct binding of E2F with the EZH2 promoter in BC and small cell lung cancer. Present research showed that overexpression of GASS5 promoted BC cells apoptosis by inhibiting transcription of EZH2. Transcriptional inhibition of EZH2 resulted from the recruitment of E2F4 to EZH2 promoter by GAS5. These findings indicated the bidirectional regulation of the transcription of EZH2 by E2Fs in BC, consistent with the findings of an earlier study which reported that E2Fs are divided into two subgroups based on their transcriptional properties: activating (E2F1-3) and repressing (E2F4-5) role of E2Fs. Our results expanded our knowledge of the regulatory network between E2Fs and EZH2 in BC, and confirmed the key role of E2F4 in BC development.

Our prior recent work had revealed the regulation of EZH2 at the post-transcriptional level by miR-101, miRNAs mostly bind to the 3′-UTR of miRNAs, and give rise to target mRNAs destabilization and/or translational inhibition. miR-101 has been regarded as tumor-suppressive miRNA, and it could directly target 3′-UTR of EZH2 mRNA and inhibit proliferation, migration, and angiogenesis of tumor cells. Interestingly, previous study has also showed EZH2 inhibited miR-101 transcription in hepatocellular carcinoma. In our present study, we found that EZH2 negatively regulated miR-101 transcription in BC. Our findings add to the accumulating evidence that suggests there is a positive feedback loop between EZH2 and miR-101.

Various EZH2 inhibitors had been developed, but none of them have been applied in clinical practice for BC patients. Gambogic acid (GA, C38H44O8), derived from the resin of Garcinia, has long been used as anti-inflammatory and parasiticide medicine. Recent researches found that GA was cytotoxic to tumor cells but had minimal toxicity to normal cells. Thus, GA is a potential chemotherapeutic agent for clinical application, and it has already finished a phase II clinical trial in China. We previously reported that GA induced BC cell apoptosis through inhibiting the expression of EZH2. In this study, we found GA positively regulating GASS5 expression, and the pro-apoptotic effect of GA was repressed by GASS5 knockdown both in vivo and in vitro. These results support the feasibility of using GASS5 to act as a promising target for development of novel anti-cancer agents in BC.

In conclusion, we first identified lncRNA GASS5 as an important prognosis maker for BC patients. Most significantly, this study then demonstrated a novel regulatory function of GASS5 on the transcriptional level of EZH2 by enhancing the binding of E2F4 to EZH2 promoter (Fig. 7). Since the interaction between GASS5 and EZH2 plays an essential role in the cell apoptosis of BC, our findings demonstrate the possibility of using GASS5 as therapeutic target for treatment of BC, and extend existing knowledge about the molecular mechanism that underlies BC progression.

Materials and methods

Reagents
GA and DMSO were purchased from Sigma (St Louis, MO, USA). GA was dissolved in DMSO at a concentration of 25 mmol/L and was stored at -20 °C. For in vitro study, GA was then dissolved in culture medium. For in vivo study, GA was then dissolved in 0.9% NaCl.

Patients and specimens
43 patients who had undergone radical cystectomy at Department of Urology, Union Hospital of Tongji Medical College from August 2012 to May 2014 were selected for this study. All the patients were diagnosed as transitional cell cancer by histopathologic biopsy, but none of the patients received anti-cancer therapy before surgical resection. Both carcinoma tissues and adjacent non-carcinoma tissues (at least 2 cm from the tumor site) were collected and evaluated by at least two experienced pathologists. All the specimens were staged according to TNM Classification of Malignant Tumours—7th edition, and graded according to the 2004 World Health...
Fig. 5 Knockdown of EZH2 improved miR-101 transcription, and overexpression of EZH2 suppressed GA-stimulated upregulation of miR-101. a–c EZH2 shRNA was stably transfected into BC cells, RT-qPCR was performed to assess EZH2 mRNA (a) and miR-101 (b) expression, luciferase reporter assay was performed to detect miR-101 transcriptional activity (c). d BC cells stably transfected with PC3.1-EZH2 or the empty PC3.1 vector was harvested and the transfection efficiency was evaluated. e, f Then, 2.0 μM GA or isopyknic PBS was added. Forty-eight hour later, miR-101 expression levels were assessed (e), and 40 h later, miR-101 transcriptional activities were detected (f). * P< 0.05 versus controls, *a significant difference between PC3.1-EZH2 and empty vector groups.

Organization Consensus Classification and Staging System for bladder neoplasms. A summary of clinical data is listed in Table 1. The research was approved by the Institutional Review Board of Tongji Medical College of Huazhong University of Science and Technology, and informed consent was obtained from each patient before surgery.
Fig. 6 (See legend on next page.)
Cell culture

The human bladder cancer cell lines T24 and EJ were maintained by our laboratory. Cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, USA), supplemented with 10% FBS (HyClone, Logan, UT, USA), 100 U mL$^{-1}$ penicillin and 100 μg mL$^{-1}$ streptomycin (Gibco). All cells were cultured in a humidified atmosphere, at 37 °C with 5% CO2.

Real-time quantitative Polymerase Chain Reaction (RT-qPCR)

The relative quantity of lncRNA and mRNA were measured by RT-qPCR, and had been described as previously$^{14}$. The gene-specific primers were designed by Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA, USA), and the sequences are list in Table 2. GAPDH served as internal control.

Gene knockdown

Small interfering RNA (siRNA) and short hairpin RNA (shRNA) were used for knockdown of genes. GAS5 siRNAs, E2F4 siRNAs and the control siRNAs were synthesized by RiboBio (RiboBio Co., Ltd., Guangzhou, China), and the sequences are list in Table 2. The annealed oligos of GAS5 shRNA (sense: 5′-ccggGGAC-CAGCTTAATGGTTCTttaaggagaAGAACCATTAAGCTGGTCCtttttg-3′, anti-sense: 5′-aattcaaaaaGGACCAGCT-TAATGGTTCTtctcttgaaAGAACCATTAAGCTGGTCC-3′) were inserted into GV122 vector, digested with AgeI and EcoRI (Genechem, Shanghai Genechem Co,. Ltd., Shanghai, China). EZH2 shRNA-1, -2 and the nontarget shRNA plasmids were presented from Dr. Bai$^{49}$. The siRNAs and shRNAs were transfected into cells with Lipofectamine 2000 (Invitrogen).

Gene overexpression

Full-length GAS5 sequence lacking a poly A tail was synthesized (based on the GAS5 sequence, NR_002578.2) and subcloned into a GV144 vector (XhoI and BamHI digestion) (Genechem). Full-length EZH2 sequence lacking a poly A tail was synthesized and subcloned into a PC3.1 vector, and that is a gift from Dr. Qiangsong Tong (Union Hospital, Wuhan, China). The plasmids were transfected into cells as previously described$^{50}$.

Cell viability assay

3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma, St. Louis, MO) was used to detect cell proliferation, and cell viability assay was performed as previously described$^{14}$.

Flow cytometric analysis

Apoptosis and necrosis were assessed by flow cytometry following Phycoerythrin (PE)-conjugated Annexin V (PE Annexin V) and 7-Amino-Actinomycin D (7AAD) staining (BD Pharmingen, San Diego, CA, USA). Cells were treated according to the manufacturer’s instructions and analyzed by flow cytometry (FACScan, Becton Dickinson, Mountain View, CA, USA).
USA). Data analysis was performed using Cell Quest analysis software (Becton Dickinson) and expressed as percentage of positive cells.

Western-blot analysis

The procedure was described previously. Briefly, equal amounts (30-60 μg) of total protein were separated by SDS-PAGE, followed with alternative immunoblot analysis with antibodies [mouse anti-human GAPDH (Cat No. #51332, Cell Signaling Technology, Danvers, MA, USA), mouse anti-human caspase-3 and cleaved caspase-3 (Cat No. #9668, Cell Signaling Technology), rabbit anti-human EZH2 (Cat No. #5246, Cell Signaling Technology), rabbit anti-human E2F4 (Cat No. sc-1082, Santa Cruz Biotechnology, Dallas, Texas, USA), rabbit anti-human GST (Cat No. sc80998, Santa Cruz Biotechnology)]. Immunoreactive bands were then visualized, and the optical densities were measured.

Quantification of miRNA expression

The levels of mature miR-101 were measured by Bulge-Loop miRNAs qPCR Primer Set (RiboBio Co., Ltd., Guangzhou, China). After cDNA was synthesized with a miRNA-specific stem-loop primer, qPCR was performed with the specific primers. The relative miRNA levels
were normalized to those of U6 (RiboBio Co., Ltd.) small nuclear RNA.

**Luciferase reporter assay**

Human EZH2 luciferase reporter plasmid was previously prepared by our team19, and human miR-101-2 reporter plasmid was a gift from Dr. Angang Yang43. Firefly and Renilla luciferase activities were measured consecutively 40–44 h after transfection, according to the Dual-Luciferase Assay instruction (Promega, Shanghai, China). The activity of Firefly luciferase was normalized by Renilla luciferase.

**RNA immunoprecipitation (RIP)**

Cells were harvested and then lysed by nuclear isolation buffer (1.28 M sucrose, 40 mM Tris-HCl, 20 mM MgCl2, 4% Triton X-100). Nuclei were pelleted by centrifugation at 2500 g for 15 min, and nuclear pellet was resuspended in RIP buffer (150 mM KCl, 25 mM Tris, 5 mM EDTA, 0.5 mM DTT, 0.5% NP-40, Protease Inhibitor, 100 U/ml RNase inhibitor). Next, resuspended nuclei were split into three fractions (for Input, IgG and, E2F4 antibody coprecipitation) and sheared by a dounce homogenizer. Then, nuclear membrane and debris were pelleted by centrifugation at 13,000 rpm for 10 min. IgG (Santa Cruz Biotechnology) or human anti-E2F4 antibody (Santa Cruz Biotechnology) was added to supernatant with incubation at 4 °C for 2 h. Followed, 40 μl of protein A beads were added and incubated for 1 h at 4 °C. After centrifugation for 30 s, three washes in 500 μl RIP buffer and one wash in PBS, beads were resuspended in 1 ml Trizol. Finally, coprecipitated RNAs were isolated and GAS5 was quantified by RT-qPCR.

**Chromatin immunoprecipitation (ChIP)**

The ChIP assay was performed according to the manufacturer’s protocol using the EZ-ChIP kit (Upstate Biotechnology, Lake Placid, NY, USA). Purified DNA was then used for RT-qPCR assay. The primers were designed by the Premier Primer 5.0 software (GAPDH: forward, 5′-GAAGGTGAAAGTCGGAGTC-3′, reverse, 5′-GAGGTGATGGATGAGGT-3′; EZH2 promoter: forward, 5′-ACTTTGGCTTCCAGCACC-3′, Reverse, 5′-CGCTGTAAGGGACGCCACTG-3′).

**RNA pull-down assay**

Biotin-labeled RNA pull-down was performed as described previously51. Briefly, cellular nuclear protein was extracted by using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Inc., USA), and then incubated with biotin-labeled GAS5 truncation probe and streptavidin agarose beads (Invitrogen). Finally, the retrieved protein was detected by Western-blot.

**GST-E2F4 fusion protein**

To verify the direct reaction between GAS5 and E2F4, the GST-E2F4 fusion protein was synthesized. Briefly, the E2F4 gene PCR product and the pGEX-6p-1 vector were both digested by EcoRI and BamHI enzymes and then ligated together. Next, the pGEX-6p-1-E2F4 plasmid was transformed into BL21 (DE3) bacteria (Life Technologies, Waltham, MA, USA). The OD600 was periodically measured until it reached 0.6–0.8, and the culture was induced with 0.5 mM IPTG for 5 h at 37 °C. Soluble lysate was purified in batches by using Glutathione Sepharose 4B beads (Cat No. 17075601, GE Healthcare) for 5 h at 4 °C. The beads were washed three times with binding buffer, and the fusion protein was separated by SDS-PAGE and identified by Western-blot.

**Immunohistochemistry**

Immunostaining was performed on mouse tissue sections that had been confirmed as bladder cancer beforehand by a pathologist. The sections were deparaffinized in xylene, rehydrated with ethanol, and then blocked with 3% H2O2 followed by blocking in goat serum and incubation with anti-EZH2 antibody overnight at 4 °C. Secondary staining was performed and colorized using Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA). The peroxidase reaction was developed with diaminobenzidine (DAB kit; Vector Laboratories) and the slides were counterstained with hematoxylin. The images were observed using a microscope (Olympus BX60, Tokyo, Japan) and quantitatively analyzed by Image-Pro Plus software (Media Cybernetics, Carlsbad, CA, USA).

**Statistical analysis**

Statistical analysis was performed using SPSS 19.0 software (SPSS Inc, Chicago, IL, USA). The χ2 test was used to evaluate the difference in clinical pathological features. Paired t test was performed to compare the difference between paired tissues by RT-qPCR analysis. The Student t test was utilized to compare continuous variables...
between different groups, summarized as means ± SD of triplicates. P < 0.05 was considered significant statistically difference.

Acknowledgements
This research was supported by the National Natural Science Foundation of China (No. 81602234, 81402113, 81472406), the Natural Science Foundation of Hubei Province (No. 2017CFB637) and Health and Family Planning Commission of Hubei Province (No. WJ2017M124).

Conflict of interest
The authors declare that they have no conflict of interest.

References
1. Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30, 27 (2016).
2. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 64, 639–653 (2013).
3. Liu, Z. et al. Downregulation of GAS5 promotes bladder cancer cell proliferation and death in human bladder cancer cells. Biochim. Biophys. Acta 1863, 2560 (2016).
45. Zhao, L., Guo, Q. L., You, Q. D., Wu, Z. Q. & Gu, H. Y. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. *Biol. Pharm. Bull.* **27**, 998 (2004).

46. Zhao, K. et al. Gambogic acid suppresses cancer invasion and migration by inhibiting TGFbeta1-induced epithelial-to-mesenchymal transition. *Oncotarget* **8**, 27120–27136 (2017).

47. Shahabipour, F. et al. Naturally occurring anti-cancer agents targeting EZH2. *Cancer Lett.* **400**, 325–335 (2017).

48. Wang, X. et al. Studies on chemical modification and biology of a natural product, gambogic acid (III): determination of the essential pharmacophore for biological activity. *Eur. J. Med. Chem.* **46**, 1280–1290 (2011).

49. Bai, J. et al. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus. *Int. J. Biochem. Cell Biol.* **65**, 104–112 (2015).

50. Xiang, W. et al. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. *Oncotarget* **6**, 4066 (2015).

51. Xiang, J. F. et al. Human colorectal cancer-specific CCAT1-L IncRNA regulates long-range chromatin interactions at the MYC locus. *Cell Res.* **24**, 513–531 (2014).